Clinical data | |
---|---|
Other names | LY3819469; LY-3819469 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein(a) in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company. [1] [2]
As of March 31 of 2025, company trials in phase 2 of randomized, double-blind, placebo-controlled study resulted in significant reduction by the lepodisiran levels of genetically inherited cardiovascular risk factor such as heart attacks, strokes, thrombosis, nearly 94% from baseline. [3]